Innate Pharma (Euronext Paris: FR0010331421 - IPH): First

Innate Pharma (Euronext Paris: FR0010331421 - IPH): First Patient
Treated in the EffiKIR Trial 
MARSEILLE, FRANCE -- (Marketwire) -- 12/17/12 --  Innate Pharma SA
(EURONEXT PARIS: IPH), the innate immunity company developing
first-in-class drugs for cancer and inflammatory diseases, today
announces that the first patient was treated in the EffiKIR trial.  
EffiKIR is a double-blind placebo-controlled randomized Phase II
trial of IPH2102/BMS-986015 as maintenance treatment in elderly
patients with Acute Myeloid Leukemia (AML) in first complete
Herve Brailly, CEO of Innate Pharma, said: "EffiKIR is the first
Phase II trial for IPH2102. This is a great step for Innate Pharma
and for the anti-KIR approach."  
About EffiKIR (study IPH2102-201): 
The protocol calls for inclusion of 150 patients, randomized into
three arms. Two arms will test single agent IPH2102/BMS-986015 at
different doses and one arm will receive placebo. The primary
efficacy endpoint is leukemia-free survival. Secondary endpoints
include safety and overall survival. 
The rationale of this trial is based on the capacity of activated
Natural Killer (NK) cells to directly kill tumor cells and trigger a
broad immune activation. This rationale is supported by clinical
studies showing that activated NK cells may significantly lower the
recurrence of various hematological malignancies, including AML,
following hematopoietic stem cell transplantation (Ref: Ruggeri et
al, Blood, 2007, Giebel et al., Blood, 2003, Velardi et al, Science,
This trial is sponsored by Innate Pharma and will be performed in
France, with the participation of the two French clinical cooperative
groups, ALFA (ALFA : Acute Leukemia French Association) and GOELAMS
(Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang - Acute
Leukemia and Blood Diseases West-Est Group), harnessing the research
effort of the French centers qualified to treat patients with AML.  
About IPH2102/BMS-986015: 
IPH2102/BMS-986015 is a fully human monoclonal antibody blocking
interaction between Killer-cell immunoglobulin-like receptors (KIR)
on NK cells with their ligands. Blocking these receptors facilitates
activation of NK cells and, potentially, destruction of tumor cells
by the latter. 
IPH2102/BMS-986015 is licensed to Bristol-Myers Squibb Company (NYSE:
BMY). As part of the agreement between Innate Pharma and
Bristol-Myers Squibb, Bristol-Myers Squibb holds exclusive worldwide
rights to develop, manufacture and commercialize IPH2102/BMS-986015
and related compounds blocking KIR receptors, for all indications.
Under the agreement, Innate Pharma will conduct the development of
IPH2102/BMS-986015 through Phase II in Acute Myeloid Leukemia
IPH2102/BMS-986015 is currently tested in a randomized, double-blind,
placebo-controlled Phase II trial in elderly patients with AML in a
maintenance setting (the EffiKIR trial) and in a Phase I trial in
combination with the anti-PD-1 antibody nivolumab (BMS-936558) in
solid tumors. 
About Innate Pharma: 
Innate Pharma S.A. is a biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and inflammatory
The Company specializes in the development of new monoclonal
antibodies targeting receptors and pathways controlling the
activation of innate immunity cells. Its innovative approach has been
validated by license agreements with two major pharmaceutical
companies, Novo Nordisk A/S and Bristol-Myers Squibb. 
Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006,
Innate Pharma is based in Marseilles, France, and had 81 employees as
of September 30, 2012. 
Learn more about Innate Pharma at 
Practical Information about Innate Pharma shares:
 ISIN code:
 Ticker code: IPH 
 This press release
contains certain forward-looking statements. Although the company
believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ materially
from those anticipated. For a discussion of risks and uncertainties
which could cause the company's actual results, financial condition,
performance or achievements to differ from those contained in the
forward-looking statements, please refer to the Risk Factors
("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
( or on Innate Pharma's website
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country. 
For additional information, please contact: 
Innate Pharma  
Laure-Helene Mercier 
Director, Investor Relations
Phone: +33 (0)4 30 30 30 87  
ATCG Press 
Marielle Bricman
Mob.: +33 (0)6 26 94 18 53 
Press spacebar to pause and continue. Press esc to stop.